Edwards Lifesciences (NYSE: EW) today announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company, following its initial investment in 2017. Since that time, Innovalve has demonstrated progress in its program with promising early clinical experience. Combined with Edwards’ existing mitral innovations, the acquisition enhances the company’s TMVR technologies to address large unmet structural heart patient needs and support sustainable long-term growth.
Read the full article: Edwards Lifesciences to Acquire Innovalve //
Source: https://www.businesswire.com/news/home/20240715027456/en/Edwards-Lifesciences-to-Acquire-Innovalve